Form 4: AtriCure Director Sven Wehrwein Reports Acquisition of Restricted Stock

Director Sven Wehrwein reports acquiring 5,401 shares of AtriCure common stock through a restricted stock award.

Summary

• Sven Wehrwein, a director of AtriCure, Inc., filed a Form 4 on May 21, 2025, reporting a transaction.
• On May 19, 2025, Wehrwein acquired 5,401 shares of AtriCure common stock through a restricted stock award under the company's 2023 Stock Incentive Plan.
• These shares will vest on the one-year anniversary of the grant date.
• Following the transaction, Wehrwein beneficially owns 34,374 shares of AtriCure common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by a director is generally viewed as a positive sign, but it's a routine transaction.

Positives

• The acquisition of restricted stock by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The acquired shares will vest one year from the grant date, suggesting a commitment to the company's long-term success.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.

Key Dates

Keywords

AtriCure, Director, Wehrwein, Restricted Stock, Form 4, Beneficial Ownership, Stock Incentive Plan